• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Talanta . Recombinase polymerase amplification integrated with microfluidics for nucleic acid testing at point of care

tetano

Editor, Senior Moderator
Talanta


. 2022 Jan 4;240:123209.
doi: 10.1016/j.talanta.2022.123209. Online ahead of print.
Recombinase polymerase amplification integrated with microfluidics for nucleic acid testing at point of care


Yuemeng Bai[SUP] 1 [/SUP], Jingcheng Ji[SUP] 1 [/SUP], Fengdan Ji[SUP] 1 [/SUP], Shuang Wu[SUP] 2 [/SUP], Yuan Tian[SUP] 1 [/SUP], Birui Jin[SUP] 3 [/SUP], Zedong Li[SUP] 4 [/SUP]



Affiliations

Abstract

Nucleic acid testing (NAT) implemented on a portable, miniaturized, and integrated device with rapid and sensitive results readout is highly demanded for pathogen detection or genetic screening at resource-limited settings, especially after the outbreak of coronavirus disease 2019 (COVID-19). The integration of recombinase polymerase amplification (RPA) with emerging microfluidics, classified by paper-based microfluidics and chip-based microfluidics, shows great potential to perform laboratory independent NAT assays at point of care with minimal labor, time and energy consumption. This review summarizes the state-of-the-art of RPA integrated with paper-based microfluidics and chip-based microfluidics, and discusses their pros and cons. Finally, existing challenges and possible ways for optimization of microfluidics-based RPA are proposed.

Keywords: Digital RPA; Isothermal amplification; Paper microfluidics; Pathogen detection.
 
Back
Top Bottom